Last reviewed · How we verify

NCT07523750: PERSIGMA RCT

A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

Not yet recruiting NA Last updated 13 April 2026
What this trial tests

NA trial testing VARIPULSE Catheter in Atrial Fibrillation in 466 participants. Not yet recruiting.

Timeline
6 April 2026
Primary endpoint
31 May 2028
31 May 2028

Quick facts

Lead sponsorBiosense Webster, Inc.
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment466
Start date6 April 2026
Primary completion31 May 2028
Estimated completion31 May 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Biosense Webster, Inc. — full company profile →

Who can join

Adults 18 to 80, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess how safe VARIPULSE pulsed field ablation (PFA) catheter is and how well it works compared to food and drug administration (FDA) approved FARAWAVE PFA catheter in participants with symptomatic persistent atrial fibrillation (PsAF; continuous irregular, rapid heartbeat that lasts over 7 days and doesn't stop on its own).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Biosense Webster, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07523750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing